Lauren Pommert1, William Bradley2. 1. Children's Hospital of Wisconsin, Department of Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. 2. Department of Obstetrics and Gynecology, Froedtert and the Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. wbradley@mcw.edu.
Abstract
PURPOSE OF REVIEW: Three primary categories of gynecologic cancer are found in pediatric and adolescent patients: stromal carcinomas including juvenile granulosa cell tumors and Sertoli-Leydig cell tumors, rhabdomyosarcomas arising from the vagina and cervix (sarcoma botryoides), and ovarian germ cell tumors which comprise a wide range of histologies. These entities are rare and treatment approaches have focused on decreasing late effects of chemotherapy treatment. Here, we review presentation, histologic classifications, diagnosis, and treatment recommendations for pediatric gynecologic cancers. RECENT FINDINGS: Event-free and overall survival for these cancers is high, and the goals of treatment are minimization of morbidity and preservation of fertility with unilateral salpingo-oophorectomies and limited staging. Surveillance of tumor markers after surgery is helpful in monitoring for disease progression and adjuvant chemotherapy is often reserved for patients at recurrence. Recent literature supports avoiding chemotherapy even in high-grade germ cell tumors in the pediatric population.
PURPOSE OF REVIEW: Three primary categories of gynecologic cancer are found in pediatric and adolescent patients: stromal carcinomas including juvenile granulosa cell tumors and Sertoli-Leydig cell tumors, rhabdomyosarcomas arising from the vagina and cervix (sarcoma botryoides), and ovarian germ cell tumors which comprise a wide range of histologies. These entities are rare and treatment approaches have focused on decreasing late effects of chemotherapy treatment. Here, we review presentation, histologic classifications, diagnosis, and treatment recommendations for pediatric gynecologic cancers. RECENT FINDINGS: Event-free and overall survival for these cancers is high, and the goals of treatment are minimization of morbidity and preservation of fertility with unilateral salpingo-oophorectomies and limited staging. Surveillance of tumor markers after surgery is helpful in monitoring for disease progression and adjuvant chemotherapy is often reserved for patients at recurrence. Recent literature supports avoiding chemotherapy even in high-grade germ cell tumors in the pediatric population.
Authors: William D Foulkes; Blaise A Clarke; Martin Hasselblatt; Jacek Majewski; Steffen Albrecht; W Glenn McCluggage Journal: J Pathol Date: 2014-05-20 Impact factor: 7.996
Authors: Martin Benesch; Herwig Lackner; Alexander Pilhatsch; Barbara Gürtl-Lackner; Wolfgang Schwinger; Christian Urban Journal: J Pediatr Hematol Oncol Date: 2015-11 Impact factor: 1.289
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-31 Impact factor: 17.586
Authors: Anisa W Mburu; Peter M Itsura; Elkanah O Orang'o; Philliph K Tonui; Elly B Odongo; Afrin F Shaffi; Hellen N Muliro; Thomas N Achia; Allan L Covens; Barry P Rosen Journal: Gynecol Oncol Rep Date: 2022-03-10